Journal article

Northern Territory Perspectives on Heart Failure with Comorbidities - Understanding Trial Validity and Exploring Collaborative Opportunities to Broaden the Evidence Base

P Iyngkaran, W Majoni, A Cass, Prashanthan Sanders, C Ronco, S Brady, N Kangaharan, M Ilton, DL Hare, MC Thomas



Congestive Heart Failure (CHF) is an ambulatory care sensitive condition, associated with significant morbidity and mortality, rarely with cure. Outpatient based pharmacological management represents the main and most important aspect of care, and is usually lifelong. This narrative styled opinion review looks at the pharmacological agents recommended in the guidelines in context of the Northern Territory (NT) of Australia. We explore the concept of validity, a term used to describe the basis of standardising a particular trial or study and the population to which it is applicable. We aim to highlight the problems of the current guidelines based approach. We also present alternatives that co..

View full abstract


Funding Acknowledgements

All co-authors have won independent and governmental research funding. Several members provide counsel to pharmaceuticals. Dr Sanders reports having served on the advisory board of Biosense-Webster, Medtronic, St Jude Medical, Sanofi-Aventis and Merck, Sharpe and Dohme. Dr Sanders reports having received lecture and/or consulting fees from Biosense-Webster, Medtronic, St Jude Medical, Boston Scientific, Merck, Sharpe and Dohme, Biotronik and Sanofi-Aventis. Dr Sanders reports having received research funding from Medtronic, St Jude Medical, Boston Scientific, Biotronik and Sorin. None pose a conflict of interest for this short paper. Dr Iyngkaran is supported by the Heart Foundation Health Professional Scholarship. Dr Sanders is supported by a Practitioner Fellowship from the National Health and Medical Research Council of Australia and by the National Heart Foundation of Australia.